**Question:** The strategy for therapy of dopamine deficiency in the substantia nigra of individuals with Parkinson's disease is indicated by which of the following?

A. Levodopa
B. Dopamine agonists
C. Monoamine oxidase inhibitors
D. Anticholinergics

**Core Concept:**

In Parkinson's disease, dopamine deficiency in the substantia nigra leads to the characteristic motor symptoms such as tremors, rigidity, bradykinesia, and postural instability. The primary goal of therapy is to replace or stimulate the dopamine levels in the affected areas of the brain.

**Why the Correct Answer is Right:**

The correct answer is Dopamine agonists (B) because they directly stimulate the remaining dopamine receptors (D2) in the brain to compensate for the low dopamine levels. Dopamine agonists mimic the actions of dopamine, improving motor function and alleviating the symptoms of Parkinson's disease.

**Why Each Wrong Option is Incorrect:**

A. Levodopa (L-Dopa) is a precursor to dopamine and gets converted to dopamine in the brain. While it is an effective treatment for Parkinson's disease, its efficacy is limited by the Bensarhan effect (decreased dopamine production) and the ON-OFF phenomenon (fluctuations in response to therapy).

B. Dopamine agonists (D1/D2 agonists) directly stimulate dopamine receptors in the brain, while Levodopa relies on the normal enzymes and transporters in the brain to convert the drug to dopamine.

C. Monoamine oxidase inhibitors (MAOIs) primarily treat depression by increasing serotonin and norepinephrine levels. They do not directly target dopamine deficiency like dopamine agonists or Levodopa.

D. Anticholinergics (e.g., D2 antagonists) primarily treat conditions like Alzheimer's disease and myasthenia gravis, not Parkinson's disease, which is primarily dopaminergic in nature.

**Clinical Pearl:**

In Parkinson's disease, dopamine deficiency in the substantia nigra leads to the motor symptoms. The treatment options focus on increasing dopamine levels or mimicking its effects. Levodopa and dopamine agonists are the primary treatments for Parkinson's disease, while MAOIs and anticholinergics are not used in this condition.

**Why You Should Remember:**

Understanding the appropriate therapy for Parkinson's disease involves knowing the underlying neurotransmitter deficiency and the role of the medications in addressing this deficiency. Levodopa and dopamine agonists are essential in treating Parkinson's disease, while MAOIs and anticholinergics are not relevant in this context.